Nuvectis Pharma, Inc.
FORT LEE, NJ · Founded 2020 · CIK 0001875558 · Biotech · Public
NXP900, an oral small molecule inhibitor of SRC Family Kinases with dual catalytic and scaffolding function inhibition
nuvectis.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $16M
- 1 Form D · Aug 2022
- 50 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 10
- 0 granted · 10 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20222023
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $15,878,637 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2525 | Sonata Biosciences Inc | — | — |
| 2526 | GENTEL BIOSCIENCES INC | — | $2.7M |
| 2527 | Insilico Medicine, Inc. | — | $20M |
| 2528 | Nuvectis Pharma, Inc. | — | $16M |
| 2529 | ImmuneBridge Inc. | — | $16M |
| 2530 | IpiNovyx Bio, Inc. | — | $7.0M |
| 2531 | Lang Artificial Intelligence, Inc. | — | $11M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Ron BentsurDirector · Executive Officer
- Michael CarsonExecutive Officer
- Kenneth HobermanDirector
- Matthew KaplanDirector
- James OlivieroDirector
- Enrique PoradosuExecutive Officer
- Shay ShemeshExecutive Officer
Patents
- Crystalline Forms Of A Tyrosine Kinase Inhibitorapplication
- Crystalline Forms Of A Tyrosine Kinase Inhibitorapplication
- Methods Of Treating Cancer Using HSF1 Pathway Inhibitorsapplication
- Crystalline Forms Of A Tyrosine Kinase Inhibitorapplication
- Crystalline Forms Of A Tyrosine Kinase Inhibitorapplication
- Tyrosine Kinase Inhibitorsapplication
- Methods Of Treating Cancer Using HSF1 Pathway Inhibitorsapplication
- Crystalline Forms Of The Tyrosine Kinase Inhibitor ECF506application
- Crystalline Salt Forms Of The Tyrosine Kinase Inhibitor ECF506application
- Methods Of Treating Cancer Using HSF1 Pathway Inhibitorsapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.